CR Sanjiu

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (referred to as "CR Sanjiu") is a large state-controlled listed pharmaceutical company, primarily engaged in the research, development, production, and sales of pharmaceutical products, as well as related health services. Since its listing, the company has been awarded the "Golden Bull Top 100" and "Value Top 100" enterprises among China's main board listed companies multiple times. As of now, CR Sanjiu has been included in the Shenzhen Component Index, CSI 500, and FTSE Russell indices.

CR Sanjiu's predecessor was Shenzhen Southern Pharmaceutical Factory, established in 1985. In 1999, it was restructured into a joint-stock company initiated by 5 companies, including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. On March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999). In 2008, it officially became part of China Resources Group. In 2010, the company name was changed from "Sanjiu Medical & Pharmaceutical Co., Ltd." to "China Resources Sanjiu Medical & Pharmaceutical Co., Ltd."

CR Sanjiu's core business is positioned in the CHC health consumer products and prescription drug sectors, with a rich product line that is continuously expanding. CHC health consumer products mainly cover categories such as colds, gastrointestinal, skin, liver and gallbladder, pediatrics, orthopedics, gynecology, cardiovascular and cerebrovascular, among others, with core products holding a significant market share. Prescription drug products cover therapeutic areas including cardiovascular and cerebrovascular, anti-tumor, digestive system, orthopedics, pediatrics, anti-infection, etc., featuring products such as Xuesaitong Sanqi series, Shenfu Injection, MitoXantrone Hydrochloride Injection for tracing, Huachansu tablets and injections, Yixuesheng Capsules, Yuxuebi, Cefobiprole Medocaril Sodium for Injection, which enjoy a high reputation in hospital settings. The company's TCM formula granules and prepared herbal slices are dedicated to creating "original quality and taste" 999 TCM formula granules and "Sanjiu Bencao Wu" premium herbal slices.

The "999" brand enjoys high recognition among consumers and in the pharmaceutical industry. Based on the "999" main brand, a "1+N" brand matrix has been constructed spanning the entire life cycle and all health management scenarios. Over the years, CR Sanjiu has consistently ranked first in the comprehensive ranking of OTC enterprises published by the China Nonprescription Medicines Association, with 999 Ganmaoling Granules/Capsules continuously winning first place in the category of cold and cough (Chinese patent medicine). Additionally, CR Sanjiu has multiple products ranked among the top in various lists.

Against the backdrop of constant changes in the pharmaceutical industry, CR Sanjiu embraces opportunities for industry and market development, leading "high-quality development" through innovation, adhering to the dual-driven approach of "brand + innovation," focusing on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical health products, optimizing business layout, strengthening brand and channel construction, increasing innovation investment, actively exploring innovative models for industry chain development, building a competitive advantage in the entire TCM industry chain, improving operational quality and efficiency, and achieving steady improvement in business performance and core capabilities. In 2024, the company achieved operating revenue of RMB 27.617 billion, a year-on-year increase of 11.63%; total profit of RMB 4.594 billion, an increase of 22.35%; net profit attributable to shareholders of the listed company of RMB 3.368 billion, an increase of 18.05%; and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of RMB 3.118 billion, an increase of 15.01%.

CR Sanjiu has always attached great importance to R&D and innovation. Scientific research projects centered on the company's products "Shenfu Injection," "Honghua Injection," "Shenmai Injection," "Xintailin," "999 Lixuwang brand Xuesaitong Sanqi Soft Capsules," and "Artemisinin series" have successively won the second prize of the National Science and Technology Progress Award. During the "14th Five-Year Plan" strategic period, the company adheres to an innovation-driven strategy, building a systematic R&D system, continuously increasing R&D investment, strengthening the construction of scientific and technological talent echelons, and enhancing innovation and development capabilities. The company has established six institutes and three laboratories, including the Health Drug Research Institute, TCM Research Institute, and Innovative Drug Research Institute, focusing on innovative fields for the research and development of generic drugs, innovative drugs, and classic TCM formulas; the TCM Resources Research Institute focuses on the research, protection, development, and utilization of TCM resources; the Advanced Delivery Research Institute focuses on forward-looking and breakthrough research and incubation of common generic drug delivery technologies; and the Process Technology Research Institute focuses on improving process technology levels and strengthening industry chain collaboration efficiency. The Deep Blue Laboratory, Fuxi Laboratory, and Shuidi Laboratory capture strategic opportunities in intelligent TCM manufacturing, aging, and consumption upgrade to explore innovation potential. In terms of TCM heritage and innovation, CR Sanjiu accelerates the cultivation of new quality productive forces, continuously deepens the full-process TCM development system, and consolidates TCM R&D capabilities.

CR Sanjiu continuously pays attention to high-quality resources at home and abroad, making strategic moves in mergers and acquisitions. Kunming Pharmaceutical Group and Tasly have successively become holding listed companies of CR Sanjiu. CR Sanjiu will empower and develop in synergy with Kunming Pharmaceutical Group and Tasly. Among them, CR Sanjiu takes CHC as its core business, striving to become a leading enterprise in the industry; Tasly takes prescription drugs as its core business, striving to become a top brand in innovative TCM drugs and medical channels; and Kunming Pharmaceutical Group takes Sanqi products and premium national drugs as its core business, aiming to become a leader in the silver economy health industry.

Looking to the future, guided by the mission of "Caring for Public Health, Creating a Better Life Together," CR Sanjiu benchmarks against leading enterprises, continuously improves its business layout, and strives towards the goal of becoming China's leading enterprise in the public pharmaceutical health industry, committed to becoming the number one brand in China's pharmaceutical health sector.